Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
October 02, 2019 at 16:05 PM EDT
BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) in National Harbor, MD from November 6 – 10, 2019. The abstracts, which will be presented in a poster session, include a clinical trial in progress description of the Phase 2 study of ADU-S100 (MIW815) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), as well as nonclinical data on the role of TNF-alpha signaling on STING agonists.
Details of the posters are as follows:
To view these abstracts, please visit the SITC 2019 website located at https://www.sitcancer.org/2019/home.
Cautionary Note on Forward-Looking Statements